8 results on '"Andrea Vele"'
Search Results
2. Comparison of the Asthma Control Questionnaire and patient diaries in uncontrolled asthma
- Author
-
Dave Singh, Alberto Papi, Guy Brusselle, J. Christian Virchow, Giorgio Walter Canonica, Eva Topole, Andrea Vele, and George Georges
- Subjects
Medicine - Published
- 2023
- Full Text
- View/download PDF
3. Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
- Author
-
Piotr Kuna, Joanna Jerzynska, Matteo Martini, Andrea Vele, Irene Barneschi, Fabrizia Mariotti, George Georges, and Giorgia Ciurlia
- Subjects
adolescents ,asthma ,pharmacodynamics ,pharmacokinetics ,systemic exposure ,triple therapy ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract The single‐inhaler extrafine formulation triple combination beclometasone dipropionate (BDP), formoterol fumarate (FF) plus glycopyrronium bromide (GB) is available for asthma management in adults. Its use in adolescents has not yet been evaluated. This study investigated the pharmacokinetic profile of BDP/FF/GB in adults and adolescents, with the aim of ruling out higher plasma exposure in adolescents compared to adults. In this open‐label, non‐randomized study, patients with asthma aged 12–17 (adolescents) and 18–64 years (adults) self‐administered a single dose of BDP/FF/GB 400/24/50 μg via pressurized metered‐dose inhaler (pMDI). The primary objective was to rule out higher systemic exposure to beclometasone 17‐monopropionate (B17MP; active metabolite of BDP), formoterol, and GB in terms of the area under the plasma concentration‐time curve from 0 to the last quantifiable concentration (AUC0–t) in adolescents versus adults. A total of 40 adolescents and 40 adults entered the study (mean age of 14.8 and 43.6 years, respectively). The primary objective (AUC0–t) was met, with the upper 90% confidence interval of the geometric mean ratio between adolescents and adults
- Published
- 2022
- Full Text
- View/download PDF
4. Normalisation of airflow limitation in asthma: Post‐hoc analyses of TRIMARAN and TRIGGER
- Author
-
Alberto Papi, Dave Singh, J. Christian Virchow, G. Walter Canonica, Andrea Vele, and George Georges
- Subjects
exacerbations ,inhaled corticosteroid ,inhaled triple therapy ,long‐acting muscarinic antagonist ,long‐acting beta2‐agonist ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Background In asthma, persistent airflow limitation (PAL) is associated with poorer control, lung function decline and exacerbations. Using post‐hoc analyses we evaluated: the relationship between post‐salbutamol PAL at screening, airflow limitation (AL) during 52 weeks treatment with extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) versus BDP/FF and the risk of moderate/severe asthma exacerbations. Methods TRIMARAN and TRIGGER were double‐blind studies comparing BDP/FF/G with BDP/FF (TRIMARAN medium‐dose ICS; TRIGGER high‐dose) in adults with uncontrolled asthma. Patients were subgrouped according to post‐salbutamol PAL status at screening, and AL over the 52‐week treatment period. Results Most patients with post‐salbutamol PAL at screening had AL at all on‐treatment visits (TRIMARAN 62.8%; TRIGGER 66.8%). A significantly higher proportion of patients had normalised airflow on ≥1 follow‐up visit when receiving BDP/FF/G than BDP/FF (TRIMARAN 44.1 vs. 33.1% [p = 0.003]; TRIGGER 40.1 vs. 26.0% [p
- Published
- 2022
- Full Text
- View/download PDF
5. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
- Author
-
Dave Singh, Johann Christian Virchow, Giorgio Walter Canonica, Andrea Vele, Maxim Kots, George Georges, and Alberto Papi
- Subjects
Asthma ,Pharmacotherapy ,Long-acting β2-agonists ,Long-acting muscarinic antagonists ,Inhaled corticosteroids ,Subgroup analyses ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to the addition of the long-acting muscarinic antagonist component within inhaled triple therapy was impacted by a range of clinical characteristics. Methods These were pre-specified and post-hoc sub-group analyses of TRIMARAN and TRIGGER, which were double-blind, 52-week studies comparing medium-strength (100/6/10 µg; TRIMARAN) and high-strength (200/6/10 µg; TRIGGER) BDP/FF/G with the respective BDP/FF strengths in adults with uncontrolled asthma and a history of ≥ 1 exacerbation. Co-primary endpoints were pre-dose forced expiratory volume in 1 s (FEV1) at Week 26 and the rate of moderate-to-severe exacerbations over 52 weeks. Key secondary endpoints: peak FEV1 at Week 26 and average morning peak expiratory flow over the first 26 weeks in each study, and severe exacerbation rate over 52 weeks (pooled data). Results Baseline clinical characteristics (pre-specified analyses) had no consistent effect on the lung function improvements with BDP/FF/G. For the exacerbation endpoints, sub-groups with higher reversibility gained greatest relative benefit from BDP/FF/G versus BDP/FF. In post-hoc analyses with patients sub-grouped by screening blood eosinophil values, in TRIMARAN the greatest relative effect of BDP/FF/G versus BDP/FF on the lung function endpoints was in the ≤ 300 cells/µL group; in TRIGGER, eosinophil levels did not markedly influence the relative efficacy of BDP/FF/G versus BDP/FF. Eosinophil levels did not influence relative efficacy on moderate-to-severe or severe exacerbations. Conclusion Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676076?term=NCT02676076&draw=2&rank=1 ,); TRIGGER, NCT02676089 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676089?term=NCT02676089&draw=2&rank=1 )
- Published
- 2020
- Full Text
- View/download PDF
6. Tolerability and hydrating effects of an anti-aging gynaecological collagen cream in women in menopause
- Author
-
Giorgio Caccia, Enrica Salvatori, Andrea Vele, Milko M. Radicioni, Anna Mancarella Eberhardt, Francesca Focanti, and Andrea F. D. Di Stefano
- Subjects
medicine.medical_specialty ,integumentary system ,Abdominal skin ,Visual analogue scale ,business.industry ,medicine.disease ,Dermatology ,Vulvovaginal discomfort ,Surgery ,Perineum ,Menopause ,Skin hydration ,medicine.anatomical_structure ,Tolerability ,medicine ,business ,Burning Sensation - Abstract
Background and Aims: A gynaecological cream containing collagen, phytocollagen, hyaluronate and vitamins was investigated in women in menopause. Methods: The cream was daily applied to the vaginal mucosa and the perineal skin as well as to the abdominal skin (healthy skin used as control) for 1 week and then on alternate days for other 2 weeks. Skin hydration and viscoelasticity were measured at baseline and after 8 and 21 days by Corneometer® CM 825 and Cutometer® MPA 850, respectively. The product use comfort and the moisturising of the vaginal mucosa were evaluated by the volunteers through a questionnaire and a visual analogue scale, respectively. Results: The local tolerability was excellent for nearly all of the volunteers (90% - 95%) and according both to dermatologist’s and gynaecologist’s evaluation. Related adverse reactions had a frequency of 15% (10% vulvovaginal burning sensation and 5% vulvovaginal discomfort). The topical hydration increased both in the perineal and the abdominal skin. Hydration increase vs. baseline was more marked on day 8 than on day 21 and was significant in the abdominal skin (p-value
- Published
- 2014
7. Scalable detection of technically challenging variants through modified next‐generation sequencing
- Author
-
Susan Rojahn, Tina Hambuch, Jessika Adrian, Erik Gafni, Alex Gileta, Hannah Hatchell, Britt Johnson, Ben Kallman, Kate Karfilis, Curtis Kautzer, Michael Kennemer, Lloyd Kirk, Daniel Kvitek, Jessica Lettes, Fenner Macrae, Fernando Mendez, Joshua Paul, Maurizio Pellegrino, Ronny Preciado, Jan Risinger, Matthew Schultz, Lindsay Spurka, Sajani Swamy, Rebecca Truty, Nathan Usem, Andrea Velenich, and Swaroop Aradhya
- Subjects
bioinformatics ,genetic testing ,molecular genetics ,next‐generation sequencing ,Genetics ,QH426-470 - Abstract
Abstract Background Some clinically important genetic variants are not easily evaluated with next‐generation sequencing (NGS) methods due to technical challenges arising from high‐ similarity copies (e.g., PMS2, SMN1/SMN2, GBA1, HBA1/HBA2, CYP21A2), repetitive short sequences (e.g., ARX polyalanine repeats, FMR1 AGG interruptions in CGG repeats, CFTR poly‐T/TG repeats), and other complexities (e.g., MSH2 Boland inversions). Methods We customized our NGS processes to detect the technically challenging variants mentioned above with adaptations including target enrichment and bioinformatic masking of similar sequences. Adaptations were validated with samples of known genotypes. Results Our adaptations provided high‐sensitivity and high‐specificity detection for most of the variants and provided a high‐sensitivity primary assay to be followed with orthogonal disambiguation for the others. The sensitivity of the NGS adaptations was 100% for all of the technically challenging variants. Specificity was 100% for those in PMS2, GBA1, SMN1/SMN2, and HBA1/HBA2, and for the MSH2 Boland inversion; 97.8%–100% for CYP21A2 variants; and 85.7% for ARX polyalanine repeats. Conclusions NGS assays can detect technically challenging variants when chemistries and bioinformatics are jointly refined. The adaptations described support a scalable, cost‐effective path to identifying all clinically relevant variants within a single sample.
- Published
- 2022
- Full Text
- View/download PDF
8. Escala de medida sobre el grado de satisfacción habitacional del núcleo familiar estratos socio - económicos 3 y 4
- Author
-
ANDREA VÉLEZ PEREIRA and MARCELA ZULUAGA DUQUE
- Subjects
Technology ,Mining engineering. Metallurgy ,TN1-997 - Abstract
La investigación de mercados no está restringida a ningún tipo específico de problema. El propósito de ésta es proporcionar información valiosa, actualizada, confiable y válida, que permita tomar las mejores decisiones al enfrentar un problema o situación especifica. En este estudio se utilizan técnicas propias de la investigación de mercados con el objetivo de identificar un proceso metodológico que permita conocer las preferencias de los clientes demandantes de vivienda y de esta forma, proporcionar una herramienta que resulte útil para el sector de la construcción ya que le brinda información valiosa para la toma de decisiones acertadas a la hora de ofrecer proyectos que logren satisfacer las necesidades de los clientes. En él se especifican y definen todos aquellos conceptos claves que hace posible el entendimiento del manual por parte del lector. Además, se ilustran algunas aplicaciones de la escala de medida del grado de satisfacción habitacional, construida por las autoras del trabajo, para los núcleos familiares en estratos socio económicos 3 y 4 en el Valle de Aburrá, con el fin de familiarizar al usuario con la forma correcta de aplicar la escala de medida.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.